Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre (Q34451707)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre |
scientific article |
Statements
1 reference
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with pre (English)
1 reference
Laurent Alric
Eric Lawitz
Edward Gane
Brian Pearlman
Wayne Ghesquiere
Dominique Guyader
Jean-Pierre Bronowicki
Laura Lester
William Sievert
Reem Ghalib
Fredrik Sund
Frank Dutko
Melissa Shaughnessy
Peggy Hwang
Anita Y M Howe
Janice Wahl
Michael Robertson
Eliav Barr
11 November 2014
1 reference